NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
NeOnc Technologies Holdings is approaching key FDA discussions for its investigational brain-cancer treatments NEO100 and NEO212, with meetings expected in October and November 2026. Following promising Phase 2a clinical results for NEO100 showing significant progression-free and overall survival benefits, the company anticipates clarifying trial d…